Home » Stocks » RDUS

Radius Health, Inc. (RDUS)

Stock Price: $19.63 USD -0.97 (-4.71%)
Updated May 10, 2021 3:14 PM EDT - Market open
Market Cap 973.13M
Revenue (ttm) 246.98M
Net Income (ttm) -87.30M
Shares Out 46.98M
EPS (ttm) -2.35
PE Ratio n/a
Forward PE 58.82
Dividend n/a
Dividend Yield n/a
Trading Day May 10
Last Price $19.63
Previous Close $20.60
Change ($) -0.97
Change (%) -4.71%
Day's Open 20.04
Day's Range 19.48 - 20.30
Day's Volume 196,092
52-Week Range 10.15 - 26.16

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

Radius (RDUS) reports a narrower loss but misses on sales in the first quarter as lead drug sales decline.

17 minutes ago - Zacks Investment Research

Radius Health (RDUS) delivered earnings and revenue surprises of 19.05% and -5.10%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

3 days ago - Zacks Investment Research

BOSTON, May 07, 2021 (GLOBE NEWSWIRE) -- Radius Health, Inc. (“Radius” or the “Company”) (Nasdaq: RDUS), today reported its financial results for the first quarter ended March 31, 2021.

3 days ago - GlobeNewsWire

Let us take a look at three small biotech companies, RDUS, CRON and OCGN, which are gearing up for their earnings release.

Other stocks mentioned: CRON, OCGN
4 days ago - Zacks Investment Research

Radius Health (RDUS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

1 week ago - Zacks Investment Research

BOSTON, April 22, 2021 (GLOBE NEWSWIRE) -- Radius Health, Inc. (“Radius” or the “Company”) (Nasdaq: RDUS), provided the following business update. The Company's first quarter 2021 earnings will take pla...

2 weeks ago - GlobeNewsWire

BOSTON, April 20, 2021 (GLOBE NEWSWIRE) -- Radius Health (Nasdaq: RDUS) announced today that it will release its first quarter financial results on Friday, May 7, 2021. The Company will host a conferenc...

2 weeks ago - GlobeNewsWire

Radius Health (RDUS) reported earnings 30 days ago. What's next for the stock?

1 month ago - Zacks Investment Research

Radius Health (RDUS) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strengt...

1 month ago - Zacks Investment Research

BOSTON, March 03, 2021 (GLOBE NEWSWIRE) -- Radius Health, Inc. (“Radius” or the “Company”) (Nasdaq: RDUS), today announced that the Company has entered into amended and restated credit facilities in the...

2 months ago - GlobeNewsWire

Radius (RDUS) reports a wider loss but beats sales estimates in the fourth quarter.

2 months ago - Zacks Investment Research

BOSTON, Feb. 25, 2021 (GLOBE NEWSWIRE) -- Radius Health, Inc. (“Radius” or the “Company”) (Nasdaq: RDUS), today reported its financial results for the fourth quarter ended December 31, 2020 as well as f...

2 months ago - GlobeNewsWire

With the trading day more than halfway over, the broad markets have pushed higher, seemingly recovering from Tuesday.

Other stocks mentioned: ANF, MAT, WDC, ALLK, EBS, EOLS, GBIO ...
2 months ago - 24/7 Wall Street

Radius Health (RDUS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

2 months ago - Zacks Investment Research

BOSTON, Feb. 17, 2021 (GLOBE NEWSWIRE) -- Radius Health, Inc. (Nasdaq: RDUS), today announced that it will provide a corporate update at the 10th Annual SVB Leerink Global Healthcare Conference at 10:40...

2 months ago - GlobeNewsWire

BOSTON, Feb. 16, 2021 (GLOBE NEWSWIRE) -- Radius Health (Nasdaq: RDUS) announced today that it will release its fourth quarter financial results on Thursday, February 25, 2021. The Company will host a c...

2 months ago - GlobeNewsWire

BOSTON, Feb. 12, 2021 (GLOBE NEWSWIRE) -- Radius Health, Inc. (“Radius” or the “Company”) (Nasdaq: RDUS) provided a business update on the abaloparatide global business. Progress was made, and continues...

2 months ago - GlobeNewsWire

5 Small Drug Stocks to Buy Amid Lingering COVID-Led Uncertainty

Other stocks mentioned: ONCT, ORGO, TPTX, USNA
2 months ago - Zacks Investment Research

Radius Health announces the acquisition of the development and commercialization rights for RAD011 from Benuvia Therapeutics. The deal economics appear favorable and should add to the top-line growth ou...

3 months ago - Seeking Alpha

Radius (RDUS) is set to acquire the global development and commercialization rights of Benuvia Therapeutics' synthetic cannabidiol oral solution for utilization in multiple endocrine and metabolic orpha...

4 months ago - Zacks Investment Research

BOSTON, Jan. 06, 2021 (GLOBE NEWSWIRE) -- Radius Health, Inc. (Nasdaq: RDUS), today announced that Kelly Martin, President and CEO will present a virtual corporate update at the 39th Annual J.P. Morgan ...

4 months ago - GlobeNewsWire

Radius (RDUS) signs an agreement with Paladin Labs, wherein the latter will now be responsible for all commercial activities related to Tymlos and abaloparatide-TD in Canada.

4 months ago - Zacks Investment Research

BOSTON, Jan. 06, 2021 (GLOBE NEWSWIRE) -- Radius Health, Inc. (“Radius” or the “Company”) (Nasdaq: RDUS) today announced a definitive agreement to acquire the global development and commercialization ri...

4 months ago - GlobeNewsWire

BOSTON, Jan. 05, 2021 (GLOBE NEWSWIRE) -- Radius Health, Inc. (“Radius” or the “Company”) (Nasdaq: RDUS) today announced that the Company has entered into definitive agreements with Endo Ventures Limite...

4 months ago - GlobeNewsWire

BOSTON, Jan. 04, 2021 (GLOBE NEWSWIRE) -- Radius Health, Inc. (“Radius” or the “Company”) (Nasdaq: RDUS) announced today that Machelle Sanders and Dr. Andrew C. von Eschenbach have joined the Company's ...

4 months ago - GlobeNewsWire

WALTHAM, Mass., Dec. 15, 2020 (GLOBE NEWSWIRE) -- Radius Health, Inc. (“Radius” or the “Company”) (Nasdaq: RDUS) provided a general business update on progress made since October 2020. The key areas of ...

4 months ago - GlobeNewsWire

Radius Health (RDUS) reported earnings 30 days ago. What's next for the stock?

5 months ago - Zacks Investment Research

Radius (RDUS) reports an in-line loss but misses sales estimates in the third quarter.

6 months ago - Zacks Investment Research

Radius Health, Inc. (RDUS) CEO Kelly Martin on Q3 2020 Results - Earnings Call Transcript

6 months ago - Seeking Alpha

Radius Health (RDUS) delivered earnings and revenue surprises of 0.00% and -5.61%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

6 months ago - Zacks Investment Research

Radius Health, Inc.'s (RDUS) CEO Kelly Martin on Q3 2020 Results - Earnings Call Transcript

6 months ago - Seeking Alpha

WALTHAM, Mass., Nov. 05, 2020 (GLOBE NEWSWIRE) -- Radius Health, Inc. (“Radius” or the “Company”) (Nasdaq: RDUS), today reported its financial and operating results for the third quarter ended September...

6 months ago - GlobeNewsWire

Radius Health (RDUS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

6 months ago - Zacks Investment Research

WALTHAM, Mass., Oct. 21, 2020 (GLOBE NEWSWIRE) -- Radius Health, Inc. (“Radius” or the “Company”) (Nasdaq: RDUS) provided a general business update on progress made since May 2020. The Company will prov...

6 months ago - GlobeNewsWire

WALTHAM, Mass., Oct. 20, 2020 (GLOBE NEWSWIRE) -- Radius Health (Nasdaq: RDUS) announced today that it will release its third quarter financial results on Thursday, November 5, 2020. The Company will ho...

6 months ago - GlobeNewsWire

Schwartzman joins the newly formed Capital, Strategy, & Transactions Group Schwartzman joins the newly formed Capital, Strategy, & Transactions Group

7 months ago - GlobeNewsWire

WALTHAM, Mass., Oct. 01, 2020 (GLOBE NEWSWIRE) -- Radius Health, Inc. (Nasdaq: RDUS) announced today that the company has successfully sold its second oncology pipeline asset – RAD 140 - to Ellipses Pha...

7 months ago - GlobeNewsWire

WALTHAM, Mass. and FLORENCE, Italy, Sept. 25, 2020 /PRNewswire/ -- Radius Health, Inc. ("Radius" or the "Company") (Nasdaq: RDUS) and the Menarini Group today announced an update on the elacestrant Phas...

7 months ago - PRNewsWire

WALTHAM, Mass., Sept. 24, 2020 (GLOBE NEWSWIRE) -- Radius Health, Inc. (“Radius” or the “Company”) (Nasdaq: RDUS), today announced that Jose (Pepe) Carmona will be stepping down as Chief Financial Off...

7 months ago - GlobeNewsWire

Radius Health (RDUS) reported earnings 30 days ago. What's next for the stock?

8 months ago - Zacks Investment Research

Radius (RDUS) completes enrollment in its phase III study assessing a wearable abaloparatide-transdermal patch in the treatment of postmenopausal women with osteoporosis at high risk for fracture.

8 months ago - Zacks Investment Research

Includes detailed results from Phase 2 histomorphometry study and Teijin’s Phase 3 trial in Japan Includes detailed results from Phase 2 histomorphometry study and Teijin’s Phase 3 trial in Japan

8 months ago - GlobeNewsWire

WALTHAM, Mass., Sept. 08, 2020 (GLOBE NEWSWIRE) -- Radius Health, Inc. (“Radius” or the “Company”) (Nasdaq: RDUS) today announced completion of enrollment in its “wearABLe” phase 3 trial.

8 months ago - GlobeNewsWire

WALTHAM, Mass., Sept. 02, 2020 (GLOBE NEWSWIRE) -- Radius Health, Inc. (Nasdaq: RDUS) today announced its participation in the following conferences in September 2020.

8 months ago - GlobeNewsWire

Radius (RDUS) reports a wider-than-expected loss but beats sales estimates in the second quarter.

8 months ago - Zacks Investment Research

Radius Health, Inc.'s (RDUS) CEO Kelly Martin on Q2 2020 Results - Earnings Call Transcript

9 months ago - Seeking Alpha

Radius Health (RDUS) delivered earnings and revenue surprises of -15.85% and 3.48%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

9 months ago - Zacks Investment Research

  Shares of Radius Health (NASDAQ:RDUS) rose 1.4% in pre-market trading after the company reported Q2 results.

9 months ago - Benzinga

WALTHAM, Mass., Aug. 10, 2020 (GLOBE NEWSWIRE) -- Radius Health, Inc. (“Radius” or the “Company”) (Nasdaq: RDUS) today announced the appointment of Sean Murphy to its Board of Directors with immediate...

9 months ago - GlobeNewsWire

Radius Health (RDUS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

9 months ago - Zacks Investment Research

About RDUS

Radius Health, Inc., a biopharmaceutical company, develops and commercializes endocrine and other therapeutics. The company's commercial product is TYMLOS, an abaloparatide injection for the treatment of postmenopausal women with osteoporosis. It is also developing abaloparatide-SC, which is in Phase III clinical trials for the treatment of osteoporosis in men; abaloparatide-TD, a short-wear-time transdermal patch that is in Phase III clinical trials to treat postmenopausal women with osteoporosis; Elacestrant (RAD1901), a selective estrogen re... [Read more...]

Industry
Drug Manufacturers-Specialty & Generic
IPO Date
Jun 6, 2014
CEO
G. Kelly Martin
Employees
310
Stock Exchange
NASDAQ
Ticker Symbol
RDUS
Full Company Profile

Financial Performance

In 2020, Radius Health's revenue was $238.65 million, an increase of 37.69% compared to the previous year's $173.32 million. Losses were -$109.21 million, -17.88% less than in 2019.

Financial Statements

Analyst Forecasts

According to 8 analysts, the average rating for Radius Health stock is "Hold." The 12-month stock price forecast is 24.29, which is an increase of 23.74% from the latest price.

Price Target
$24.29
(23.74% upside)
Analyst Consensus: Hold